SteroTherapeutics Receives FDA Orphan-Drug Designation

NEXT STORY
$27.9 Bn Microfluidics Market – Global Forecast to 2023
PREV STORY
Amarin’s REDUCE-IT Cardiovascular Outcomes Study Reaches 100% Mark for Estimated Onset of Target Primary Major Adverse Cardiovascular Events
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

XORTX Launches XRx-101 Following the Filing of a Provisional Patent to Potentially Treat Respiratory and Kidney Disease Injury Due to Coronavirus Infection

author_avatar
NASDAQ Market News

Applied Therapeutics Reports Third Quarter 2020 Financial Results

author_avatar
NASDAQ Market News

Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences

author_avatar
NASDAQ Market News